NEW YORK (360Dx) – Fronteo Healthcare and the Japanese Foundation for Cancer Research today announced the start of a collaboration to develop a platform leveraging genomic analysis and artificial intelligence to improve the diagnosis of cancer.
The aim of the collaboration is to develop a tool that may help doctors guide patients to the best treatment options. The system being developed would enable clinical decision-making based on genetic information about cancer cells, and it will use Fronteo's AI engine called KIBIT that searches for academic papers that may shed light on the most appropriate treatments for individual patients, based on a genetic test result.
Last October, JFCR established the Cancer Precision Medicine Center, and Fronteo said that it had begun developing an AI-based system to help the center's mission to develop new cancer diagnostic technologies. The system being developed will integrate and analyze data, such as clinical sequencing data and liquid biopsy data.
Additionally, Fronteo is developing an informed consent support system based on its AI technology. Completion of the development of both the diagnostic and informed consent platforms is planned for the end of 2021.